FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

Recruitment for the trial is set to commence shortly, aiming to assess the therapy in treating various conditions.

The US Food and Drug Administration (FDA) has granted clearance to CureVac's investigational new drug application (IND) for ...

The National Cancer Institute’s Investigational New Drug program facilitates collaboration, not collusion, with industry for ...

ST-001, an intravenous nanoformulation of fenretinide, will be evaluated in a phase 1a/1b small cell lung cancer trial.

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

BrainStorm has attempted to gain market approval for NurOwn without success but remains committed to developing the cell therapy.

MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with ...

clearance for the Investigational New Drug (IND) application for ALX2004, the company’s potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of epidermal growth ...

The FDA cleared the investigational new drug application for ALX2004, with phase 1 trials expected to begin in mid-2025 for ...

BrainStorm (BCLI) submitted an Investigational New Drug, or IND, amendment to the FDA for NurOwn, the company’s autologous mesenchymal stem ...

has cleared its second Investigational New Drug (IND) application for MNV-201, an autologous hematopoietic stem cell product augmented with allogeneic mitochondria. The IND supports the initiation ...